Documents in this background package include:
Memoramdum
[WORD] [PDF] [HTML]
General
background document:
TAB
1 Endpoints that have supported
cancer drug approval (JCO article)
TAB 2 Monday
Morning [WORD] [PDF] [HTML]
Introductory
Overview: Endpoints to Measure Therapeutic Efficacy in Prostate Cancer
TAB
3 Monday Afternoon [WORD] [PDF] [HTML]
Primary
Treatment (Neoadjuvant and Adjuvant) and Hormone-Sensitive Prostate Cancer
TAB
4 Tuesday Morning [WORD] [PDF] [HTML]
Hormone-Refractory Prostate Cancer
Prostate Cancer Endpoint Proposal
TAB
5 ASCO abstract: Stewart A, et al. “The Clinical Significance of a PSA Nadir
> 0.2 to Patients With a Rising Post-operative or Post-radiation PSA Treated
with Androgen Deprivation”